Skip to main content
Premium Trial:

Request an Annual Quote

Nuvelo Takes in $74.8M in Gross Proceeds from Common Stock Offering

NEW YORK, March 9 (GenomeWeb News) - Nuvelo has completed its common stock offering, resulting in approximately $74.8 million in gross proceeds, the company said yesterday.


Nuvelo sold 5.75 million shares in total, including 5 million shares from its public offering and 750,000 shares offered to underwriters as an option.


UBS Securities was the sole book-running manager in the offering, while CIBC World Markets, Needham & Company, and JMP Securities were co-managers.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.